Company: GMRE
Filing Date: 2025-11-14
Form Type: 424B5
Source: 0001104659-25-112543
Chunk: 52

Company: Global Medical REIT Inc.
Filing Date: 2025-11-14
Form: 424B5
Chunk 52
---
 may find important in deciding whether to purchase the securities we offer, you should review the full text of these documents. The
registration statement and the exhibits and other documents can be obtained from the SEC as indicated under the sections entitled “Where
You Can Find More Information” and “Incorporation by Reference of Information Filed with the SEC.”

This prospectus only provides you with a general
description of the securities we may offer, which is not meant to be a complete description of each security. Each time we sell securities,
we will provide a prospectus supplement that contains specific information about the terms of those securities. The prospectus supplement
may also add, update or change information contained in this prospectus. If there is any inconsistency between the information in this
prospectus and any prospectus supplement, you should rely on the information in the prospectus supplement. You should read carefully both
this prospectus and any prospectus supplement together with the additional information described under the sections entitled “Where
You Can Find More Information” and “Incorporation by Reference of Information Filed with the SEC.”

<div align='center'>Incorporation
by Reference of Information Filed with the SEC</div>

The SEC allows us to “incorporate by reference”
the information we file with the SEC, which means that we can disclose important information to you by referring to those documents. The
information incorporated by reference is an important part of this prospectus and any accompanying prospectus supplement. Any statement
contained in a document which is incorporated by reference into this prospectus and any accompanying prospectus supplement is automatically
updated and superseded if information contained in this prospectus or any accompanying prospectus supplement, or information that we later
file with the SEC, modifies or replaces this information. We incorporate by reference the following documents we filed with the SEC:

| · | the description of our 7.50% Series A Cumulative Redeemable Preferred Stock, par value $0.001 per share (the “Series A Preferred    
 Stock”) in our Registration Statement on Form 8-A filed with the SEC on September 14, 2017, including any amendment or report filed 
 for the purpose of updating such description.                                                                                       |

We are also incorporating by reference additional
documents that we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), after the date of this prospectus and